104 related articles for article (PubMed ID: 27289168)
1. ART score and hepatocellular carcinoma: An appraisal of its applicability.
Yin W; Ye Q; Wang F; Liang J; Xu B; Zhang X; Zhang Q; Liu Y; Li G; Han T
Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):705-714. PubMed ID: 27289168
[TBL] [Abstract][Full Text] [Related]
2. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.
Hucke F; Sieghart W; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M
J Hepatol; 2014 Jan; 60(1):118-26. PubMed ID: 24012941
[TBL] [Abstract][Full Text] [Related]
3. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
Sieghart W; Hucke F; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Trauner M; Peck-Radosavljevic M
Hepatology; 2013 Jun; 57(6):2261-73. PubMed ID: 23316013
[TBL] [Abstract][Full Text] [Related]
4. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
[TBL] [Abstract][Full Text] [Related]
5. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Nishida N; Kitano M; Kudo M
Oncology; 2015; 89 Suppl 2():4-10. PubMed ID: 26584030
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
[TBL] [Abstract][Full Text] [Related]
8. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
9. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.
Adhoute X; Penaranda G; Naude S; Raoul JL; Perrier H; Bayle O; Monnet O; Beaurain P; Bazin C; Pol B; Folgoc GL; Castellani P; Bronowicki JP; Bourlière M
J Hepatol; 2015 Apr; 62(4):855-62. PubMed ID: 25463541
[TBL] [Abstract][Full Text] [Related]
11. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
[TBL] [Abstract][Full Text] [Related]
13. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
15. Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization.
Kirstein MM; Schweitzer N; Ay N; Boeck C; Lappas K; Hinrichs JB; Voigtländer T; Wacker F; Manns MP; Rodt T; Vogel A
Scand J Gastroenterol; 2017 Jan; 52(1):116-124. PubMed ID: 27598949
[TBL] [Abstract][Full Text] [Related]
16. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan.
Tseng CL; Lai WJ; Huang CJ; Huang YH; Su CW; Lee IC; Tseng HS; Li CP; Lee RC; Lin HC; Chao Y
Medicine (Baltimore); 2015 Nov; 94(47):e1659. PubMed ID: 26632677
[TBL] [Abstract][Full Text] [Related]
17. Role of assessment for retreatment with Transarterial chemoembolization score in decision of Retreatment with trans-arterial chemo-embolization Sessions in patients with hepatocellular carcinoma.
Abbasi AH; Abid S; Haq TU; Awan S
J Ayub Med Coll Abbottabad; 2017; 29(3):378-383. PubMed ID: 29076665
[TBL] [Abstract][Full Text] [Related]
18. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
20. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
